Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

Table 3

Proportional hazard regression model for OS and DSS of MIBC patients by treatment information: RC vs. TMT.

Characteristics	No. of patients	Overall survival (OS)		Disease-specific survival (DSS)
		HR	95% CI	HR	95% CI
RC-MIBC cohort	891	1.00 [reference]		1.00 [reference]
TMT-MIBC cohort	891	1.17	0.91-1.43	1.20	0.97-1.49
Neoadjuvant chemotherapy (NAC)
Yes	36	1.10	0.51-2.03	1.08	0.45-2.14
No	855	1.18	0.90-1.48	1.19	0.86-1.53
Adjuvant chemotherapy (AC)
Yes	515	1.08	0.88-1.47	1.09	0.86-1.50
No	376	1.21	0.77-1.69	1.23	0.74-1.71
Radiation dose
<60 Gy	467	1.24	0.83-1.61	1.25	0.81-1.64
≥60 Gy	424	1.06	0.79-1.43	1.09	0.77-1.45
Response to chemoradiation
Complete	642	0.99	0.72-1.32	1.00	0.73-1.50
Incomplete	249	1.34	0.68-1.71	1.36	0.64-1.80

Analyses were based on the Cox PH regression. All baseline covariates were well balanced in the propensity score-matched sample. Therefore, only treatment information was controlled for in the final Cox PH regression model. OS: overall survival; DSS: disease-specific survival; HR: hazard ratio; CI: confidence interval; CI: confidence interval; RC: radical cystectomy; TMT: bladder-sparing trimodality therapy; MIBC: muscle-invasive bladder cancer.